FSHD region gene 1 family member J, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FRG1JP profile across patient tissues and cancer cell-line models. FRG1JP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FRG1JP is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, FRG1JP RNA expression shows 14,164 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, LIHC, and THYM as cancer lineages where FRG1JP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG1JP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG1JP survival associations across molecular data types. FRG1JP RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG1JP RNA expression–survival associations across cancer types. High FRG1JP expression shows unfavorable associations in LIHC, LUSC and ACC, but favorable associations in MESO, UCS and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for FRG1JP RNA expression.
This table summarizes FRG1JP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FRG1JP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG1JP shows lower tumor expression in UCEC, BRCA, LUSC and LUAD and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher FRG1JP RNA expression in tumor versus normal tissue (log2 FC = +0.950, t-test p < 0.001).
This table shows molecular features associated with FRG1JP in patient tissues and cancer cell lines. In patient samples, FRG1JP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
